The fund’s investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
Name | % Net Assets |
---|---|
Roche Holding | 6.6% |
Johnson & Johnson | 5.5% |
Novartis | 5.4% |
Bristol Myers Squibb | 4.0% |
Amgen | 3.9% |
Gilead Sciences | 3.6% |
UnitedHealth Group | 3.2% |
Pfizer | 3.1% |
Merck | 2.8% |
Bayer | 2.7% |
Key | % Net Assets |
---|---|
Roche Holding | 6.6% |
Johnson & Johnson | 5.5% |
Novartis | 5.4% |
Bristol Myers Squibb | 4.0% |
Other | 78.5% |
Date | 30-Oct-2024 |
---|---|
NAV | 295.70p |
Currency | GBP |
Change | -3.30p |
% | -1.10% |
YTD change | 19.90p |
YTD % | 7.22% |
Fund Inception | 22/05/2000 |
---|---|
Fund Manager | John Bowler |
TER | 1.68 (15-Feb-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | -0.04 |
You are here: research